miR-152 normally targets oncogenic pathways (e.g., it can target DNA methyltransferase 1 and TGFα) and that its loss has been linked to increased proliferation, invasion, and therapy resistance in prostate cancer [52]. This evidence concerns the gene DNMT1 and prostate carcinoma.